BioCryst Pharmaceuticals (BCRX) Hereditary Angioedema Trial Positive
Post# of 68
Posted On: 05/27/2014 9:45:48 AM
Hereditary angioedema (HAE) is an inherited disease that causes repeated episodes of swelling. It occurs in about 1 in 10,000 to 1 in 50,000 people.
Angioedema means swelling beneath the surface of the skin. In HAE, the swelling and associated inflammation can be confined to the face, hands, feet, arms and legs. However, dangerous swelling in the airways—trachea (windpipe) or larynx (voice box)—or intestinal tract can also occur.
BioCryst Pharmaceuticals, Inc. (BCRX) reported preliminary results from its OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE). The trial met the primary efficacy endpoint, several secondary endpoints and all other objectives established for the trial.
According to the principal investigator for the trial, the OPuS-1 represents a milestone study in establishing the proof of concept that prophylaxis with an oral kallikrein inhibitor can effectively reduce attacks for patients living with HAE.
Discovered by BCRX, BCX4161 is a novel, selective inhibitor of plasma kallikrein. By inhibiting plasma kallikrein, BCX4161 suppresses bradykinin production. Bradykinin is the mediator of acute swelling attacks in HAE patients.
BCRX looks forward to working with clinical investigators, the HAE community and regulatory authorities in advancing BCX4161 to the next stage and starting the OPuS-2, 12-week trial later this year
BCRX designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and rare diseases, with the goal of addressing unmet medical needs of patients and physicians.
More about BioCryst Pharmaceuticals, Inc. (BCRX) at www.biocryst.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a social networking service which business model is based on selling advertising to businesses targeting both locally and nationally.
The CRWE-PR Finance website ( www.finance.crwe-pr.com ), in development stage and currently online, allows CRWE the instant distribution of information to the entire CRWE Network, which has reached the 606th community website in the U.S., associated with 2175 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
The North Atlantic Treaty Organization (NATO) is an intergovernmental military alliance based on the North Atlantic Treaty which was signed on 4 April 1949. The organization constitutes a system of collective defence whereby its member states agree to mutual defense in response to an attack by any external party.
The NATO Information Assurance Product Catalogue (NIAPC) provides NATO Systems Operations Centers with various information assurance products, protection profiles, and packages that provide for the safe handling of classified and non-classified NATO information. Products undergo three levels of evaluation to determine the highest level of NATO information they can protect.
FireEye, Inc. (FEYE) reported that its FireEye Forensic Analysis (AX Series) Threat Prevention Platform (TM) has received a full NATO evaluation and has been certified for inclusion in the NIAPC to handle information classified as NATO SECRET.
With this inclusion, the FireEye AX Series provides NATO nations and civil and military bodies with next-generation threat evaluation that meets the INFOSEC Directive.
FireEye AX Series is designed for security analysts to safely execute suspicious files or Web objects and inspect them for malicious activity. Utilizing the FireEye Multi-vector Virtual Execution(TM) engine, organizations are able to generate forensic details around the techniques advanced malware uses to breach a network.
FEYE has invented a purpose-built, virtual machine-based security platform that provides real-time threat protection to enterprises and governments worldwide against the next generation of cyber attacks.
More about FireEye, Inc. (FEYE) at www.fireeye.com
**
Read Full Disclaimer at www.pennyomega.com/disclaimer
Angioedema means swelling beneath the surface of the skin. In HAE, the swelling and associated inflammation can be confined to the face, hands, feet, arms and legs. However, dangerous swelling in the airways—trachea (windpipe) or larynx (voice box)—or intestinal tract can also occur.
BioCryst Pharmaceuticals, Inc. (BCRX) reported preliminary results from its OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE). The trial met the primary efficacy endpoint, several secondary endpoints and all other objectives established for the trial.
According to the principal investigator for the trial, the OPuS-1 represents a milestone study in establishing the proof of concept that prophylaxis with an oral kallikrein inhibitor can effectively reduce attacks for patients living with HAE.
Discovered by BCRX, BCX4161 is a novel, selective inhibitor of plasma kallikrein. By inhibiting plasma kallikrein, BCX4161 suppresses bradykinin production. Bradykinin is the mediator of acute swelling attacks in HAE patients.
BCRX looks forward to working with clinical investigators, the HAE community and regulatory authorities in advancing BCX4161 to the next stage and starting the OPuS-2, 12-week trial later this year
BCRX designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and rare diseases, with the goal of addressing unmet medical needs of patients and physicians.
More about BioCryst Pharmaceuticals, Inc. (BCRX) at www.biocryst.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a social networking service which business model is based on selling advertising to businesses targeting both locally and nationally.
The CRWE-PR Finance website ( www.finance.crwe-pr.com ), in development stage and currently online, allows CRWE the instant distribution of information to the entire CRWE Network, which has reached the 606th community website in the U.S., associated with 2175 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
The North Atlantic Treaty Organization (NATO) is an intergovernmental military alliance based on the North Atlantic Treaty which was signed on 4 April 1949. The organization constitutes a system of collective defence whereby its member states agree to mutual defense in response to an attack by any external party.
The NATO Information Assurance Product Catalogue (NIAPC) provides NATO Systems Operations Centers with various information assurance products, protection profiles, and packages that provide for the safe handling of classified and non-classified NATO information. Products undergo three levels of evaluation to determine the highest level of NATO information they can protect.
FireEye, Inc. (FEYE) reported that its FireEye Forensic Analysis (AX Series) Threat Prevention Platform (TM) has received a full NATO evaluation and has been certified for inclusion in the NIAPC to handle information classified as NATO SECRET.
With this inclusion, the FireEye AX Series provides NATO nations and civil and military bodies with next-generation threat evaluation that meets the INFOSEC Directive.
FireEye AX Series is designed for security analysts to safely execute suspicious files or Web objects and inspect them for malicious activity. Utilizing the FireEye Multi-vector Virtual Execution(TM) engine, organizations are able to generate forensic details around the techniques advanced malware uses to breach a network.
FEYE has invented a purpose-built, virtual machine-based security platform that provides real-time threat protection to enterprises and governments worldwide against the next generation of cyber attacks.
More about FireEye, Inc. (FEYE) at www.fireeye.com
**
Read Full Disclaimer at www.pennyomega.com/disclaimer
(0)
(0)BioCryst Pharmaceuticals Inc. (BCRX) Stock Research Links
Scroll down for more posts ▼